Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Threshold Pharmaceuticals has initiated patient enrollment for a phase II trial evaluating the efficacy and safety of glufosfamide in patients with previously treated soft tissue sarcoma.
Subscribe to our email newsletter
Soft tissue sarcoma includes cancers of cartilage, fat, muscle, blood vessels, or other connective or supportive tissue.
“The treatment of advanced, soft tissue sarcoma remains a major unmet medical need that disproportionately affects younger patients,” said Arizona Cancer Center clinical investigator Lee Cranmer. “I am hopeful that glufosfamide may provide a new treatment option for these patients.”
The primary efficacy endpoint of the trial is objective response rate. The secondary endpoints of the trial include duration of response, progression-free survival, overall survival and various safety parameters.
One exploratory objective of the trial is to evaluate the biological effects of glufosfamide on metabolic profile. An additional exploratory objective of the trial is to correlate efficacy endpoints with expression of tumor-associated glucose transporter proteins.